Clinical Trial

Comparing the Availability of AQ280 in the Body After Single Oral Doses of a Capsule Formulation Versus a Tablet for Oral Suspension Formulation

Completed Phase 1
View on ClinicalTrials.gov →
Summary
This is a Phase 1, investigator- and participant-blinded, placebo-controlled, randomized, crossover study to compare bioavailability of AQ280 following single oral doses of a capsule formulation versus a tablet for oral suspension formulation in healthy participants.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-07-29; most recent amendment 2026-05-06.
Status change: Active, Not Recruiting → Completed 2025-08-04
Trial Details
NCT Number NCT07093008
Lead Sponsor AQILION AB
Conditions Eosinophilic Esophagitis
Enrollment 9 participants
Start Date 2025-06-13
Primary Completion 2025-07-16 (estimated)
Study Completion 2025-07-22 (estimated)
Updated on ClinicalTrials.gov 2026-06-01